A Nature Biotechnology paper reported an AAV‑delivered suppressor tRNA engineered to read through UGA stop codons in vivo, offering a disease‑agnostic strategy for nonsense‑mutation conditions. The team demonstrated expression and functional suppression in preclinical models, positioning tRNA‑based therapeutics as an alternative when gene replacement or editing face delivery or safety constraints. Authors argue this approach could address the many genetic disorders caused by nonsense mutations without needing gene‑specific constructs. The paper frames AAV‑tRNA delivery as a platform that warrants GLP toxicology and long‑term expression studies before clinical translation.